Overview

In the first funding period (2019 to 2022) of the Collaborative Research Centre 1350, researchers from basic science fields and clinical disciplines at Universität Regensburg and Friedrich-Alexander-Universität Erlangen-Nürnberg joined forces to study the tubulointerstitium. In the present funding period (2023 to 2026), the successful research of CRC 1350 is continued as Transregio TRR 374 - funded by the German Research Foundation (DFG).

Spokesperson
Prof. Dr. Richard Warth
Medical Cell Biology
Universitätsstr. 31
D-93053 Regensburg
Tel.: ++49 941/943 2894
Email: richard.warth@ur.de

Vice Spokespersons
Prof. Dr. Frank Schweda
Institute of Physiology
Universitätsstr. 31
D-93053 Regensburg
Tel.: ++49 941/943 2957
Email: frank.schweda@ukr.de

Prof. Dr. Kerstin Amann
Nephropathology
Krankenhausstr. 8-10
D-91054 Erlangen
Tel.: ++49 9131/85 22291
Email: kerstin.amann@uk-erlangen.de

Prof. Dr. Mario Schiffer
Medizinische Klinik 4 - Nephrologie und Hypertensiologie
Ulmenweg 18
D-91054 Erlangen
Tel.: ++49 9131/85 39002
Email: mario.schiffer@uk-erlangen.de

Executive Board:
Kerstin Amann, Erlangen (vice spokesperson)
Silke Härteis, Regensburg
Janina Müller-Deile, Erlangen
Michaela Kritzenberger, Regensburg (gender equality officer)
Matthias Mack, Regensburg
Mario Schiffer, Erlangen (vice spokesperson)
Frank Schweda, Regensburg (vice spokesperson)
Bettina Firmke (representative of the doctoral students)
Richard Warth, Regenburg (spokesperson)
Michael Wiesener, Erlangen